The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -1.93 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as Nuvation Bio Inc. reports it. History and quarterly detail are in the app.
- License$38.2M
- Product Revenue$24.7M
- Product$24.7M
- Research And Development Service Revenue$5.3M
- Royalty Revenue$1.1M
Leadership changes
From Nuvation Bio Inc.'s own filings, the day they're filed.
- Philippe Sauvage · Chief Financial Officer · appointmenteff. 2024-10-07
- Oleg Nodelman · Directors · departureeff. 2023-12-11
- Moses Makunje · Principal Accounting Officer · appointmenteff. 2023-11-27
Latest filings
- 8-K · Company announcement2026-05-27
- 10-Q · Quarterly report2026-05-04
- 8-K · Company announcement2026-05-04
- DEF 14A · Annual proxy (pay & governance)2026-04-10
- 10-K · Annual report2026-03-02
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Nuvation Bio Inc., every answer cited🔒
- The Intelligence Brief — added when Nuvation Bio Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.